Medicare Advantage insurer + ACO REACH operator; Counterpart Health AI assistant for clinicians; ~$1.6B market cap.
Key Milestones
Vivek Garipalli + Kris Gale found Clover Health Jan 2014 in Jersey City NJ as Medicare Advantage insurtech. Bet: proprietary 'Clover Assistant' clinical decision support tool can reduce costs by directing PCPs to evidence-based care, especially for chronic conditions in seniors. Raises $100M Series A Greenoaks + First Round.
Clover Health Series F Sep 2019 $500M led by Greenoaks + others at $1.2B valuation. Clover Assistant clinical decision tool live in 8 states; serves 50K+ MA members. Vivek Garipalli CEO continues clinical-led MA strategy. Pre-SPAC fundraise sets stage for Chamath Palihapitiya merger.
Clover Health goes public via SPAC merger with Chamath Palihapitiya's Social Capital Hedosophia III Jan 7 2021 at $10/share; market cap $3.7B. Hindenburg short report Feb 4 2021 alleges DOJ investigation Clover failed to disclose — stock drops 12%, sparks regulatory scrutiny of SPAC disclosures.
Hindenburg Research short report Feb 4 2021 alleges Clover Health failed to disclose DOJ investigation pre-SPAC merger. Clover stock falls 12% on report; DOJ inquiry resolved 2022 without enforcement action. Triggers SEC review of SPAC disclosure practices broadly. Class action lawsuits drag on.
Clover Health WallStreetBets short-squeeze Jun 2021 — meme stock surge drives CLOV to $25 (Jun 8 2021); Reddit retail traders pile in. Stock collapses to $5 by 2022 amid MA enrollment slowdown + DOJ inquiry resolution. Mar 2023 Andrew Toy replaces Vivek Garipalli as CEO.
Clover Health Dec 2022 — discontinues Direct Contracting Entity (DCE) participation in CMS innovation pilot; refocuses on core Medicare Advantage. Vivek Garipalli CEO acknowledges focus discipline needed. Stock $1 (vs $26 SPAC peak Jan 2021).
Andrew Toy becomes Clover Health CEO Mar 2023 replacing co-founder Vivek Garipalli. Toy (former CTO) refocuses on Clover Assistant clinical decision tool + disciplined MA underwriting. By 2025 Clover hits first GAAP profit. Stock $4 (vs $26 Jan 2021 SPAC peak).
Clover Health FY2024 — Andrew Toy CEO reports 80K+ MA members across 7 states; medical loss ratio 80%. First quarterly GAAP profit Q3 2024. Stock $4 (vs $26 Jan 2021 SPAC peak — but trajectory positive). Clover Assistant clinical decision tool drives MLR improvement.
Clover Health Q3 2025 — Andrew Toy CEO reports 100K+ MA members; medical loss ratio 80%; first full-year GAAP profit guidance for 2025. Stock $4 (vs $26 SPAC peak Jan 2021). Clover's MA strategy stabilizes; clinical decision support tool drives MLR improvement.
Clover Health Q1 2026 — Andrew Toy CEO (since Mar 2023; replaced Vivek Garipalli) reports first quarterly GAAP profit. Clover Assistant clinical decision tool drives MLR improvement to 80%. MA membership 100K+ across 8 states (NJ, GA, SC, TX, AZ, etc.). Stock $4 vs $26 Jan 2021 SPAC peak — but trajectory now positive.